ClinicalTrials.gg

Program

Dimethyl Fumarate

Also written as “dimethyl fumarate”, “BG00012” and “FP187”.

Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Psoriasis · Multiple Sclerosis, Chronic Progressive · Arthritis, Rheumatoid, led by 3 companies.

Furthest: phase 4, since May 9, 201337 company-led studies, 1 open or runningNext primary completion: Jul 28, 2034 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen331 open or runningphase 4since May 9, 2013Sep 9, 2005Jul 28, 2034phase 3 · NCT07483632
Almirall20 open or runningphase 3since Nov 12, 2012Nov 12, 2012none ahead
Forward-Pharma20 open or runningphase 3since Mar 19, 2013Sep 24, 2010none ahead

Also a collaborator on its studies: gb-pharma-services-consulting-s-r-l, almirall-hermal-gmbh and harrison-clinical-research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Sep 9, 2005.

  1. Jun 20, 2014Phase 1 study in HealthyBiogen · NCT02171208 · 80 enrolled · United States
  2. Nov 3, 2014Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02283853 · 156 enrolled · United States, Belgium, Bulgaria and more
  3. Jan 9, 2015Phase 4 study in Multiple SclerosisBiogen · NCT02343159 · 84 enrolled · United States
  4. Apr 2, 2015Phase 2 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02410200 · 22 enrolled · United States, Belgium, Bulgaria and more
  5. Apr 23, 20153 phase 3 studiesBiogen · NCT02428231, NCT02428218, NCT02430532
  6. May 11, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02472938
  7. Jun 11, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02471560 · 36 enrolled · Norway
  8. Jul 10, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02525874 · 218 enrolled · United States, Belgium, Bulgaria and more
  9. Sep 17, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02555215 · 20 enrolled · United States, Belgium, Bulgaria and more
  10. Oct 16, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02579681 · 221 enrolled · Italy
  11. Oct 25, 2016Phase 1 study in PsoriasisAlmirall · NCT02955693 · 32 enrolled · United Kingdom
  12. Mar 7, 2019Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT03870763 · 11 enrolled · United States, Colombia, Estonia and more
  13. Dec 12, 2022Phase 4 study in Multiple SclerosisBiogen · NCT05658484 · 60 enrolled · China
  14. Feb 26, 2026Phase 3 study in Relapsing Forms of Multiple SclerosisBiogen · NCT07483632 · 185 planned

Ahead

  1. Jul 28, 2034Primary completion: phase 3 study in Relapsing Forms of Multiple SclerosisBiogen · NCT07483632

TargetBeta

KEAP1 →read by rule
“Kelch-like ECH-associated protein 1 inhibitor”ChEMBL 37, by rule

Other programs on KEAP1

ProgramCompanyFurthest phaseStudies
diroximel fumarateruleBiogenphase 35

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07483632Relapsing Forms of Multiple Sclerosis3Not yet recruitingBiogenJul 28, 2034185
NCT05658484Multiple Sclerosis · China4CompletedBiogenMar 27, 202560
NCT03870763Multiple Sclerosis, Relapsing-Remitting · United States, Colombia, Estonia and more3TerminatedBiogenJul 21, 202211
NCT02955693Psoriasis · United Kingdom1CompletedAlmirallOct 201632
NCT02579681Multiple Sclerosis, Relapsing-Remitting · Italy3CompletedBiogenDec 21, 2016221
NCT02555215Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more3CompletedBiogenSep 24, 201820
NCT02525874Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more3CompletedBiogenApr 24, 2017218
NCT02471560Multiple Sclerosis, Relapsing-Remitting · Norway4CompletedBiogenJun 12, 201736
NCT02472938Multiple Sclerosis, Relapsing-Remitting4WithdrawnBiogenJul 20190
NCT02430532Multiple Sclerosis, Chronic Progressive · United States, Belgium, Czech Republic and more3TerminatedBiogenJan 201658
NCT02428231Multiple Sclerosis · United States, Belgium, Czech Republic and more3TerminatedBiogenDec 201562
NCT02428218Multiple Sclerosis, Relapsing-Remitting3WithdrawnBiogenJan 20270
NCT02410200Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more2CompletedBiogenSep 23, 201622
NCT02343159Multiple Sclerosis · United States4TerminatedBiogenApr 15, 201684
NCT02283853Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more3CompletedBiogenJul 8, 2025156
NCT02171208Healthy · United States1CompletedBiogenJul 201480
NCT02125604Multiple Sclerosis, Relapsing-Remitting · Germany4CompletedBiogenFeb 2016214
NCT02097849Relapsing Forms of Multiple Sclerosis · United States2CompletedBiogenMay 2, 201671
NCT02090348Multiple Sclerosis, Relapsing-Remitting4WithdrawnBiogenOct 20170
NCT01930708Multiple Sclerosis, Relapsing-Remitting · Austria, Belgium, Canada and more4CompletedBiogenMar 31, 20161,114
NCT01924832Healthy · United Kingdom1CompletedBiogenApr 201432
NCT01873417Relapsing Forms of Multiple Sclerosis · United States4CompletedBiogenNov 2013237
NCT01838668Multiple Sclerosis, Relapsing-Remitting · Czechia, Japan, Korea, Republic of and more3CompletedBiogenJun 16, 2015225
NCT01815723Psoriasis · Canada3WithdrawnForward-PharmaJun 20170
NCT01726933Psoriasis · Austria, Germany, Netherlands and more3CompletedAlmirallOct 2014839
NCT01568112Healthy · United States3CompletedBiogenOct 2012173
NCT01453426Healthy · Australia, China1CompletedBiogenApr 201271
NCT01281111Healthy · United States1CompletedBiogenMar 18, 201156
NCT01230138Plaque Psoriasis · Germany2CompletedForward-PharmaJan 2012252
NCT01156311Multiple Sclerosis, Relapsing-Remitting · United States2CompletedBiogenMar 2012108
NCT01069913Healthy1CompletedBiogenOct 200914
NCT00837785Multiple Sclerosis, Relapsing-Remitting · Germany1CompletedBiogenOct 31, 200948
NCT00835770Multiple Sclerosis, Relapsing-Remitting · United States, Australia, Austria and more3CompletedBiogenNov 8, 20191,736
NCT00810836Arthritis, Rheumatoid · Australia, Canada, Czech Republic and more2CompletedBiogenFeb 2010153
NCT00451451Multiple Sclerosis, Relapsing-Remitting · United States, Belarus, Belgium and more3CompletedBiogenAug 20111,417
NCT00420212Multiple Sclerosis, Relapsing-Remitting · United States, Australia, Austria and more3CompletedBiogenFeb 20111,234
NCT00168701Multiple Sclerosis · Czechia, Germany, Hungary and more2CompletedBiogenMar 31, 2006260

How it is read

Names in the registry

  • “dimethyl fumarate”, 19 entries
  • “BG00012”, 8 entries
  • “FP187”, 5 entries
  • “Dimethyl Fumarate”, 2 entries
  • “Dimethyl fumarate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.